Technical Analysis for SAVA - Cassava Sciences, Inc.

Grade Last Price % Change Price Change
grade D 1.24 0.00% 0.00
SAVA closed unchanged on Monday, August 19, 2019, on 37 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical SAVA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
200 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%

Older signals for SAVA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
Cassava Sciences, Inc. develops drugs for nervous system disorders in the United States. It engages in developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Biology Pain Neuroscience Alzheimer's Disease Psychiatry Psychiatric Diagnosis
Is SAVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 12 Cassava Sciences EPS beats by $0.03
Aug 12 Cassava Sciences Announces Second Quarter 2019 Financial Results
Aug 5 Lexicon Pharmaceuticals and MediWound among healthcare gainers; GlycoMimetics leads the losers
Aug 2 Aphria leads healthcare gainers; Acorda Therapeutics and Ekso Bionics Holdings among losers
Jul 8 What Kind Of Shareholder Owns Most Cassava Sciences, Inc. (NASDAQ:SAVA) Stock?
Jun 27 Cassava Sciences (SAVA) Presents At Maxim Group's Alzheimer's Disease Conference - Slideshow
Jun 25 Stifel likes Viking Therapeutics in premarket analyst action
Jun 18 Cassava Sciences to Present at Maxim Group’s Conference on Alzheimer’s Disease
Jun 10 FDA Ad Com tomorrow on utility of higher-dose opioids
May 28 Cassava Sciences Announces New Website Launch
See more SAVA news...
Indicators
Indicator Value
52 Week High 2.99
52 Week Low 0.76
Average Volume 260,964
200-Day Moving Average 1.1597
50-Day Moving Average 1.2923
20-Day Moving Average 1.3111
10-Day Moving Average 1.2633
Average True Range 0.0977
ADX 24.96
+DI 10.2363
-DI 24.4457
Chandelier Exit (Long, 3 ATRs ) 1.1869
Chandelier Exit (Short, 3 ATRs ) 1.4231
Upper Bollinger Band 1.4448
Lower Bollinger Band 1.1774
Percent B (%b) 0.23
BandWidth 20.395088
MACD Line -0.0255
MACD Signal Line -0.0097
MACD Histogram -0.0158
Fundamentals Value
Market Cap 8.18 Million
Num Shares 6.59 Million
EPS -2.01
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 0.00
Price-to-Book 2.02
PEG Ratio -0.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.42
Resistance 3 (R3) 1.41 1.34 1.39
Resistance 2 (R2) 1.34 1.29 1.35 1.38
Resistance 1 (R1) 1.29 1.27 1.26 1.30 1.37
Pivot Point 1.22 1.22 1.20 1.23 1.22
Support 1 (S1) 1.17 1.17 1.14 1.18 1.11
Support 2 (S2) 1.10 1.15 1.11 1.10
Support 3 (S3) 1.05 1.10 1.09
Support 4 (S4) 1.06